Using the Laser in Correcting Anemia in Hemodialysis Patients

2004

Closed access Metadata (CSL-JSON)
DOI 10.1111/j.1492-7535.2004.0085aw.x
Data confidence 70 medium
How this score is calculated

It is built from checkable properties of the record itself: whether the article has a DOI, how many independent sources confirmed its data, whether the required fields are filled in, and how recent the latest confirmation is. Disagreement between sources and a missing identifier lower it. A value of 80 or above means the record was published without further checking; 60 to 79 means it is published at reduced confidence, with a manual check advisable. A record verified by an editor by hand is never pushed below 90 by a recalculation. This scores our data about the article, not the article itself.

Abstract

One of the main symptoms of terminal‐stage chronic renal insufficiency is anemia. One of the best applicable methods correcting anemia is using recombinant human erythropoietin preparation. Using recombinant human erythropoietin in patients with terminal‐stage chronic renal insufficiency in 90–95% of events had a positive effect, but 5–10% of patient had refraction to erythropoietin, which has spurred the search for new efficient methods correcting anemia. The purpose of the study was to determine the influence of the laser on erythropoiesis and blood acid–alkaline condition (pH) in patients with terminal‐stage chronic renal insufficiency. In the course of the study, erythrocytes, hemoglobin, reticulocytes in blood, and blood acid–alkaline condition (pH) were determined. At the beginning of the treatment, all hematological parameters 5 and 15 days after marrow stimulation were defined. 15 days after marrow stimulation with laser, increasing amounts of erythrocytes, hemoglobin, and hematocrit were observed. The initial erythrocyte count was 2.22 ± 0.1 × 1012/L, hemoglobin 67.7 ± 3.2 g/L and hematocrit 18.2 ± 1.2%. During the laser treatment, erythrocyte count increased up to 2.9 ± 0.8 × 1012/L, hemoglobin up to 89.6 ± 2.9 g/L and hematocrit up to 28.2 ± 1.3% (p < 0005).